Nimotuzumab

Unassigned

New Medicines

CIMAher · Pancreatic cancer - first-line in combination with gemcitabine

Information

CIMAher
New molecular entity
Oncoscience
Gilead Science

Development and Regulatory status

None
Phase III Clinical Trials
None
Yes

Category

Epidermal growth factor receptor (EGFR)-targeting monoclonal antibody
The annual incidence rate of PC is ~ 12 per 100,000. In 2008, there were 7,179 new diagnoses in England and Wales (CancerResearchUK). The majority of patients present at an advanced stage and < 3% survive to 5 years. Around 10-15% of patients receive chemotherapy (NICE TA25 May 01).
Pancreatic cancer - first-line in combination with gemcitabine
Intravenous infusion

Further information

Yes
To be confirmed

Evidence based evaluations